Orally Administered Bifidobacteria as Vehicles for Delivery of Agents to Systemic Tumors
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Certain bacteria have emerged as biological gene vectors with natural tumor specificity, capable of specifically delivering genes or gene products to the tumor environment when intravenously (i.v.) administered to rodent models. We show for the first time that oral administration of bacteria to mice resulted in their translocation from the gastrointestinal tract (GIT) with subsequent homing to and replication specifically in tumors. The commensal, nonpathogenic Bifidobacterium breve UCC2003 harboring a plasmid expressing lux fed to mice bearing subcutaneous (s.c.) tumors were readily detected specifically in tumors, by live whole-body imaging, at levels similar to i.v. administration. Reporter gene expression was visible for >2 weeks in tumors. Mice remained healthy throughout experiments. Cytokine analyses indicated a significant upregulation of interferon-gamma (IFN-gamma) in the GIT of bifidobacteria-fed mice, which is associated with increases in epithelial permeability. However, B. breve feeding did not increase systemic levels of other commensal bacteria. The presence of tumor was not necessary for translocation to systemic organs to occur. These findings indicate potential for safe and efficient gene-based treatment and/or detection of tumors via ingestion of nonpathogenic bacteria expressing therapeutic or reporter genes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Haller, D., Bode, C., Hammes, W. P., Pfeifer, A. M. A., Schiffrin, E. J., & Blum, S. (2000) · Gut · doi:10.1136/gut.47.1.79 · Cited by 466
The prevalence of gut translocation in humans
Sedman, P. C., Macfle, J., Sagar, P., Mitchell, C. J., May, J., Mancey-Jones, B., & Johnstone, D. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90110-4 · Cited by 362
Exploring the Diversity of the Bifidobacterial Population in the Human Intestinal Tract
Turroni, F., Foroni, E., Pizzetti, P., Giubellini, V., Ribbera, A., Merusi, P., Cagnasso, P., Bizzarri, B., de'Angelis, G. L., Shanahan, F., et al. (2009) · Applied and Environmental Microbiology · doi:10.1128/aem.02216-08 · Cited by 311
Safety of probiotics: translocation and infection: Nutrition Reviews©, Vol. 66, No. 4
Liong, M.-T. (2008) · Nutrition Reviews · doi:10.1111/j.1753-4887.2008.00024.x · Cited by 265
Steffen, E. K., Berg, R. D., & Deitch, E. A. (1988) · Journal of Infectious Diseases · doi:10.1093/infdis/157.5.1032 · Cited by 234
Yi, C., Huang, Y., Guo, Z.-Y., & Wang, S.-R. (2005) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2005.00094.x · Cited by 65
Cited by
Molecular principles of metastasis: a hallmark of cancer revisited
Fares, J., Fares, M. Y., Khachfe, H. H., Salhab, H. A., & Fares, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0134-x · Cited by 2,379
The microbiome, cancer, and cancer therapy
Helmink, B. A., Khan, M. A. W., Hermann, A., Gopalakrishnan, V., & Wargo, J. A. (2019) · Nature Medicine · doi:10.1038/s41591-019-0377-7 · Cited by 1,200
Gut Bifidobacteria Populations in Human Health and Aging
Arboleya, S., Watkins, C., Stanton, C., & Ross, R. P. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01204 · Cited by 668
Programmable probiotics for detection of cancer in urine
Danino, T., Prindle, A., Kwong, G. A., Skalak, M., Li, H., Allen, K., Hasty, J., & Bhatia, S. N. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa3519 · Cited by 467
O'Connell Motherway, M., Zomer, A., Leahy, S. C., Reunanen, J., Bottacini, F., Claesson, M. J., O'Brien, F., Flynn, K., Casey, P. G., Moreno Munoz, J. A., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105380108 · Cited by 376
Metadata
- Authors
- Cronin, M., Morrissey, D., Rajendran, S., El Mashad, S. M., van Sinderen, D., O'Sullivan, G. C., & Tangney, M.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2010-07
- Volume
- 18
- Issue
- 7
- Pages
- 1397-1407
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2124662953
- Cited by
- 117
- References
- 6
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.